Development of a novel clinical assay for measuring serum hepcidin levels
Award amount
$276,193Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AFFINERGY, LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- YJQ6K1QMS488
- Solicitation number
- PA13-088
- Topic code
- NIDDK
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A novel peptide assay for hepcidin clinical monitoring
- A Rapid Point of Care Test for APOL1 Renal Risk Alleles
- Novel clinical assay to rapidly monitor posaconazole levels in plasma
- Immunoprofiling to develop a novel diagnostic array for cardiac sarcoidosis
- Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
75 SBIR/STTR records share this UEI (2005–2023). Reported award amounts total $59,804,968. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services